Quest Diagnostics (NYSE:DGX) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.45. The company issued revenue guidance of $7.6-7.75 billion, compared to the consensus revenue estimate of $7.68 billion.
Shares of DGX opened at $94.76 on Thursday. Quest Diagnostics has a 12-month low of $78.95 and a 12-month high of $116.49. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.87 and a current ratio of 0.78. The stock has a market cap of $12.53 billion, a P/E ratio of 15.02, a PEG ratio of 2.21 and a beta of 0.90.
Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.04. Quest Diagnostics had a return on equity of 14.99% and a net margin of 9.59%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period in the previous year, the company posted $152.00 earnings per share. The company’s quarterly revenue was up .4% compared to the same quarter last year. Analysts anticipate that Quest Diagnostics will post 6.4 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, April 22nd. Investors of record on Monday, April 8th were paid a dividend of $0.53 per share. The ex-dividend date was Friday, April 5th. This represents a $2.12 annualized dividend and a yield of 2.24%. Quest Diagnostics’s dividend payout ratio is 33.60%.
DGX has been the topic of several research reports. Barclays restated a buy rating and set a $114.00 price target on shares of Quest Diagnostics in a research note on Friday, February 15th. Mizuho set a $106.00 price target on Quest Diagnostics and gave the company a buy rating in a research note on Friday, February 15th. Canaccord Genuity restated a buy rating and set a $97.00 price target on shares of Quest Diagnostics in a research note on Monday, February 18th. Jefferies Financial Group upgraded Quest Diagnostics from a hold rating to a buy rating and boosted their price target for the company from $93.00 to $107.00 in a research note on Tuesday, April 2nd. Finally, Zacks Investment Research upgraded Quest Diagnostics from a sell rating to a hold rating in a research note on Thursday, January 17th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $103.17.
In other news, SVP Michael E. Prevoznik sold 336 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $88.23, for a total value of $29,645.28. Following the sale, the senior vice president now directly owns 42,108 shares in the company, valued at approximately $3,715,188.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Catherine T. Doherty sold 66,382 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $90.59, for a total value of $6,013,545.38. Following the completion of the sale, the senior vice president now owns 133,908 shares in the company, valued at $12,130,725.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 88,106 shares of company stock worth $7,935,229. Corporate insiders own 1.86% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Quest Diagnostics (DGX) Updates FY 2019 Earnings Guidance” was originally reported by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://macondaily.com/2019/04/25/quest-diagnostics-dgx-updates-fy-2019-earnings-guidance.html.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Featured Article: What is a Call Option?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.